Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Merck |
---|---|
Information provided by: | Merck |
ClinicalTrials.gov Identifier: | NCT00772967 |
This study will evaluate a walking model of osteoarthritis for use in testing of new therapeutic agents.
Condition | Intervention | Phase |
---|---|---|
Osteoarthritis |
Drug: non-product or non-Merck product Drug: Comparator: Placebo Drug: Comparator: Ultracet (tramadol/acetaminophen) |
Phase I |
Study Type: | Interventional |
Study Design: | Diagnostic, Randomized, Double Blind (Subject, Investigator), Placebo Control, Crossover Assignment, Efficacy Study |
Official Title: | A Double-Blind, Placebo-Controlled, 3-Period Crossover Study to Evaluate the Analgesic Effects of Naproxen and Ultracet in a Walking Model of Osteoarthritis Knee Pain |
Estimated Enrollment: | 18 |
Study Start Date: | June 2008 |
Estimated Study Completion Date: | December 2008 |
Estimated Primary Completion Date: | December 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Group 1: 3 days placebo, 3 days Naproxen, 3 days Ultracet
|
Drug: non-product or non-Merck product
Naproxen tablets 500 mg twice daily on Days 1 and 2 and 500 mg once daily on Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
Drug: Comparator: Placebo
Placebo capsules twice daily on Day 1, three times daily on Day 2, and 2 capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
Drug: Comparator: Ultracet (tramadol/acetaminophen)
Ultracet (tramadol/acetaminophen) 37.5/325 mg/mg capsules twice daily on Day 1, three times daily on Day 2, and two 37.5/325 mg capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
|
2: Experimental
Group 2: 3 days naproxen, 3 days Ultracet, 3 days placebo
|
Drug: non-product or non-Merck product
Naproxen tablets 500 mg twice daily on Days 1 and 2 and 500 mg once daily on Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
Drug: Comparator: Placebo
Placebo capsules twice daily on Day 1, three times daily on Day 2, and 2 capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
Drug: Comparator: Ultracet (tramadol/acetaminophen)
Ultracet (tramadol/acetaminophen) 37.5/325 mg/mg capsules twice daily on Day 1, three times daily on Day 2, and two 37.5/325 mg capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
|
3: Experimental
Group 3: 3 days Ultracet, 3 days placebo, 3 days naproxen
|
Drug: non-product or non-Merck product
Naproxen tablets 500 mg twice daily on Days 1 and 2 and 500 mg once daily on Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
Drug: Comparator: Placebo
Placebo capsules twice daily on Day 1, three times daily on Day 2, and 2 capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
Drug: Comparator: Ultracet (tramadol/acetaminophen)
Ultracet (tramadol/acetaminophen) 37.5/325 mg/mg capsules twice daily on Day 1, three times daily on Day 2, and two 37.5/325 mg capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
|
4: Experimental
Group 4: 3 days placebo, 3 days Ultracet, 3 days naproxen
|
Drug: non-product or non-Merck product
Naproxen tablets 500 mg twice daily on Days 1 and 2 and 500 mg once daily on Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
Drug: Comparator: Placebo
Placebo capsules twice daily on Day 1, three times daily on Day 2, and 2 capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
Drug: Comparator: Ultracet (tramadol/acetaminophen)
Ultracet (tramadol/acetaminophen) 37.5/325 mg/mg capsules twice daily on Day 1, three times daily on Day 2, and two 37.5/325 mg capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
|
5: Experimental
Group 5: 3 days naproxen, 3 days placebo, 3 days Ultracet
|
Drug: non-product or non-Merck product
Naproxen tablets 500 mg twice daily on Days 1 and 2 and 500 mg once daily on Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
Drug: Comparator: Placebo
Placebo capsules twice daily on Day 1, three times daily on Day 2, and 2 capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
Drug: Comparator: Ultracet (tramadol/acetaminophen)
Ultracet (tramadol/acetaminophen) 37.5/325 mg/mg capsules twice daily on Day 1, three times daily on Day 2, and two 37.5/325 mg capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
|
6: Experimental
Group 6: 3 days Ultracet, 3 days naproxen, 3 days placebo
|
Drug: non-product or non-Merck product
Naproxen tablets 500 mg twice daily on Days 1 and 2 and 500 mg once daily on Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
Drug: Comparator: Placebo
Placebo capsules twice daily on Day 1, three times daily on Day 2, and 2 capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
Drug: Comparator: Ultracet (tramadol/acetaminophen)
Ultracet (tramadol/acetaminophen) 37.5/325 mg/mg capsules twice daily on Day 1, three times daily on Day 2, and two 37.5/325 mg capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
|
Ages Eligible for Study: | 45 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | Merck & Co., Inc. ( Executive Vice President, Clinical and Quantitative Sciences ) |
Study ID Numbers: | 2008_566, 105 |
Study First Received: | October 13, 2008 |
Last Updated: | December 24, 2008 |
ClinicalTrials.gov Identifier: | NCT00772967 |
Health Authority: | United States: Institutional Review Board |
Osteoarthritis, Knee Naproxen Musculoskeletal Diseases Tramadol Osteoarthritis |
Joint Diseases Arthritis Pain Rheumatic Diseases Acetaminophen |
Sensory System Agents Analgesics, Non-Narcotic Therapeutic Uses Physiological Effects of Drugs Central Nervous System Depressants Narcotics |
Peripheral Nervous System Agents Analgesics Central Nervous System Agents Analgesics, Opioid Pharmacologic Actions |